Fibroblast growth factor receptors (FGFR) are transmembrane kinase proteins with growing importance in cancer biology given the frequency of molecular alterations and vast interface with multiple other signaling pathways. Furthermore, numerous FGFR inhibitors in clinical development demonstrate the expanding therapeutic relevance of this pathway. Indeed, results from early phase clinical trials already indicate that a subset of patients with advanced tumors derive benefit from FGFR targeted therapies. FGFR gene aberrations and FGFR gene rearrangements are relatively rare in solid malignancies. The recently described FGFR3-TACC3 fusion protein has a constitutively active tyrosine kinase domain and promotes aneuploidy. We summarize the prevalence data on FGFR3-TACC3 fusions among different histological tumor types and the preliminary evidence that this rearrangement represents a targetable molecular aberration in some patients with solid tumors.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342462 | PMC |
| http://dx.doi.org/10.18632/oncotarget.10482 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CRISPR-Cas13a Targeting the FGFR3-TACC3 Fusion Gene Inhibits Proliferation of Bladder Cancer Cells in vitro and in vivo.
Onco Targets Ther
December 2024
Department of Surgery, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical School of Guangzhou University of Chinese Medicine, Shenzhen, People's Republic of China.
Introduction: The FGFR3-TACC3 fusion gene exists in a variety of malignant tumors, including bladder cancer. In our ongoing research on the CRISPR-Cas13a gene-editing system, we reported the use of CRISPR-Cas13a gene-editing system to knockout FGFR3-TACC3 and inhibit the proliferation of bladder tumor cells.
Purpose: This study aimed to use the CRISPR-Cas13a gene-editing system to target the FGFR3-TACC3 fusion gene in bladder cancer cells, which has the potential to be a new and effective treatment for bladder cancer.
Deep Diving Into the Fusion Across Cancer Types in the Indian Population From Formalin-Fixed Paraffin-Embedded RNA-Exome Data: A Road to Discovering Novel Rearrangements With Clinical Relevance.
JCO Glob Oncol
November 2024
4baseCare Onco Solutions Pvt. Ltd, Bangalore, India.
Article Synopsis
- Gene fusions, important mutations in cancer, are under-researched in India, despite rising cancer cases.
- This study analyzed RNA-exome data from 1,392 Indian cancer patients to identify and validate gene fusions using advanced tools and methods.
- Findings revealed a high prevalence of FGFR fusions and 91 novel potential driver fusions, highlighting their significance as diagnostic markers and therapeutic targets across various cancer types.
Prospective study of the real impact of fusion centered genomic assays in patient management in a national collaborative group: the GETHI-XX-16 study.
Clin Transl Oncol
November 2024
Laboratory of Innovation in Oncology; Gynecological, Genitourinary and Skin Tumor Unit, HM CIOCC (Clara Campal Comprehensive Cancer Centre), Sanchinarro HM Universitary Hospital, HM Hospitales, Madrid, Spain, Madrid, Spain.
Article Synopsis
- Precision medicine is changing how we treat cancer, but many patients still lack access to the necessary genetic testing and treatments.
- A study in Spain examined how providing free RNA sequencing tests impacted the treatment of solid cancer patients who had already failed standard therapies, analyzing samples from 395 patients.
- The results showed actionable genetic alterations in 14.4% of patients, leading to limited use of targeted therapies, highlighting a need for better access to comprehensive molecular testing and personalized treatments.
FGFR3::TACC3 fusions in head and neck carcinomas: a study of nine cases highlighting phenotypic heterogeneity, frequent HPV association, and a morphologically distinct subset in favor of a putative entity.
Virchows Arch
October 2024
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
The FGFR3::TACC3 fusion has been reported in subsets of diverse cancers including urothelial and squamous cell carcinomas (SCC). However, the morphology of FGFR3::TACC3-positive head and neck carcinomas has not been well studied and it is unclear if this fusion represents a random event, or if it might characterize a morphologically distinct tumor type. We describe nine FGFR3::TACC3 fusion-positive head and neck carcinomas affecting six males and three females aged 38 to 89 years (median, 59).
View Article and Find Full Text PDFPluripotent stem cell-derived CTLs targeting FGFR3-TACC3 fusion gene in osteosarcoma.
Int Immunopharmacol
December 2024
Orthopedic Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17, Yongwaizheng Street, Nanchang, Jiangxi Province 330006, China; Artificial Joints Engineering and Technology Research Center of Jiangxi Province, No. 17, Yongwaizheng Street, Nanchang, Jiangxi Province 330006, China. Electronic address:
Article Synopsis
- Osteosarcoma is a challenging and aggressive bone cancer, and this study explores a new treatment using engineered induced pluripotent stem cells (iPSCs) combined with the FGFR3-TACC3 fusion gene to create cytotoxic T lymphocytes (CTLs) that fight the cancer.
- The research confirmed the presence of the FGFR3-TACC3 fusion gene in osteosarcoma samples and successfully modified iPSCs to produce CTLs that targeted and killed osteosarcoma cells in lab experiments.
- The in vitro results showed these CTLs not only killed cancer cells but also prevented their movement and proliferation, with further validation achieved in animal tests; suggesting a potential for personalized immunotherapy approaches for osteosar
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!